Adverum Biotechnologies Inc
NASDAQ:ADVM
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.75
28.1
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ADVM stock under the Base Case scenario is 8.56 USD. Compared to the current market price of 6.04 USD, Adverum Biotechnologies Inc is Undervalued by 29%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Adverum Biotechnologies Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ADVM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Adverum Biotechnologies Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Adverum Biotechnologies Inc
Balance Sheet Decomposition
Adverum Biotechnologies Inc
Current Assets | 161.1m |
Cash & Short-Term Investments | 153.2m |
Other Current Assets | 7.8m |
Non-Current Assets | 73.3m |
PP&E | 62.9m |
Other Non-Current Assets | 10.4m |
Current Liabilities | 27.7m |
Accounts Payable | 2.1m |
Accrued Liabilities | 25.5m |
Non-Current Liabilities | 62.6m |
Other Non-Current Liabilities | 62.6m |
Earnings Waterfall
Adverum Biotechnologies Inc
Revenue
|
1m
USD
|
Operating Expenses
|
-104.1m
USD
|
Operating Income
|
-103.1m
USD
|
Other Expenses
|
9m
USD
|
Net Income
|
-94.1m
USD
|
Free Cash Flow Analysis
Adverum Biotechnologies Inc
USD | |
Free Cash Flow | USD |
ADVM Profitability Score
Profitability Due Diligence
Adverum Biotechnologies Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
Adverum Biotechnologies Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
ADVM Solvency Score
Solvency Due Diligence
Adverum Biotechnologies Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Adverum Biotechnologies Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ADVM Price Targets Summary
Adverum Biotechnologies Inc
According to Wall Street analysts, the average 1-year price target for ADVM is 30.89 USD with a low forecast of 10.1 USD and a high forecast of 42 USD.
Dividends
Current shareholder yield for ADVM is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ADVM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company is headquartered in Redwood City, California and currently employs 188 full-time employees. The company went IPO on 2014-07-31. The firm develops gene therapy product candidates. Its lead product candidate, ADVM-022, is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. ADVM-022 is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD) who are responsive to anti-VEGF therapy. The firm's second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (BCM) via a single IVT injection.
Contact
IPO
Employees
Officers
The intrinsic value of one ADVM stock under the Base Case scenario is 8.56 USD.
Compared to the current market price of 6.04 USD, Adverum Biotechnologies Inc is Undervalued by 29%.